ArticlePharmacoEconomics2022

Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.

Elamin H ElbashaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.